{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04194203\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["atezolizumab","bevacizumab"]],"indication":"chemotherapy-naïve stage IV non-squamous non-small cell lung cancer","name":"IMpower151","nct_id":"NCT04194203","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=impower151-nct04194203. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.","label":"Treatment A","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.","label":"Treatment B","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-06-27","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":305,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":["Avastin"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2024-07-19","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-02-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) in the intent to treat (ITT) population, as determined by the investigator","timeFrame":"Randomization until the first occurence of disease progression or death from any cause, whichever occures first (up to approximately 33 months)"}],"references":[],"start_date":{"date":"2020-04-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","url":"https://clinicaltrials.gov/study/NCT04194203"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/impower151-nct04194203"}